嚢胞性線維症(CF症)治療薬の世界市場2016-2020

◆英語タイトル:Global Cystic Fibrosis Therapeutics Market 2016-2020
◆商品コード:IRTNTR10588
◆発行会社(調査会社):Technavio
◆発行日:2016年10月5日
◆ページ数:80
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥285,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥342,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥456,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。



当調査レポートでは、嚢胞性線維症(CF症)治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、嚢胞性線維症(CF症)治療薬の世界市場規模及び予測、薬剤種類別分析、地域別分析/市場規模、主要国別分析、購買基準、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。
【レポートの概要】

About Cystic Fibrosis
Cystic fibrosis, also known as mucoviscidosis, is a genetically inherited, chronic disease and is progressive in nature. The onset of cystic fibrosis typically occurs in early childhood or, rarely, at birth. The primary symptoms of cystic fibrosis include breathing difficulties, high salt content in the sweat, and secretion of abnormally viscous mucus. The principal indicators of cystic fibrosis in patients are pancreatic insufficiency, pancreatitis, chronic bronchitis, adolescent diabetes, male sterility, and very rarely liver cirrhosis or intestinal obstruction. The most usual forms of cystic fibrosis are those with respiratory complications, difficulties related to digestion, and anomalies in height and growth. The mortality and morbidity of a patient are dependent on the degree of bronchopulmonary involvement.

Technavio’s analysts forecast the global cystic fibrosis therapeutics market to grow at a CAGR of 31.9% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global cystic fibrosis therapeutics market for 2016-2020. The report has taken into consideration the revenue generated by the vendors in the PET packaging market for packaging of different goods.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Cystic Fibrosis Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• AbbVie
• F. Hoffmann-La Roche
• Gilead Sciences
• Novartis
• Vertex Pharmaceuticals

[Other prominent vendors]
• Advanced Inhalation Therapies (AIT)
• Alaxia SAS
• Alcresta Therapeutics
• AlgiPharma
• Allergan
• Anthera
• AstraZeneca
• Bayer
• Celtaxsys
• Chiesi Farmaceutici
• Corbus Pharmaceuticals
• Cyclacel Pharmaceuticals
• Digestive Care
• Galapagos
• Grifols
• Insmed Incorporated
• Kamada
• Nivalis Therapeutics
• Novoteris
• Parion Sciences
• Pharmaxis
• ProQR Therapeutics
• Protalix Biotherapeutics
• Proteostasis Therapeutics
• PTC Therapeutics
• Pulmatrix
• Savara
• SolAeroMed
• Vectura

[Market driver]
• Special regulatory designations for drugs
• For a full, detailed list, view our report

[Market challenge]
• Discontinuation of drugs from development
• For a full, detailed list, view our report

[Market trend]
• Co-pay and assistance programs by vendors
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Disease overview
• Understanding the disease
• Pathophysiology
• Diagnosis
• Manifestations of cystic fibrosis

PART 06: Pipeline analysis

PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 08: Market segmentation by drug class
• CFTR modulators
• Mucolytics
• PERT
• Anti-infectives
• Bronchodilators

PART 09: Market segmentation by molecule type
• Small molecules
• Biologics

PART 10: Geographical segmentation
• Global cystic fibrosis therapeutics market by geography
• Cystic fibrosis therapeutics market in Americas
• Cystic fibrosis therapeutics market in EMEA
• Cystic fibrosis therapeutics market in APAC

PART 11: Key leading countries
• The US
• The UK
• France
• Canada
• Italy

PART 12: Market drivers
• Special regulatory designations for drugs
• Increased uptake of CFTR modulators
• Improvement in diagnostic technologies

PART 13: Impact of drivers

PART 14: Market challenges
• Discontinuation of drugs from development
• Difficulty in developing drugs due to rarity of disease

PART 15: Impact of drivers and challenges

PART 16: Market trends
• Co-pay and assistance programs by vendors
• Strategic collaborations
• Advances in technology for drug development and delivery

PART 17: Vendor landscape
• Competitive scenario
• Other prominent vendors

PART 18: Key vendor analysis
• Vertex Pharmaceuticals
• F. Hoffmann-La Roche
• AbbVie
• Gilead Sciences
• Novartis

PART 19: Appendix
• List of abbreviations

PART 20: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Key buying criteria for global cystic fibrosis therapeutics market 2015
Exhibit 03: Key customer segments of cystic fibrosis therapeutics market
Exhibit 04: Snapshot of cystic fibrosis
Exhibit 05: Defects caused by CFTR mutation
Exhibit 06: Diagnosis of cystic fibrosis
Exhibit 07: Pipeline portfolio: Global cystic fibrosis therapeutics market
Exhibit 08: Global cystic fibrosis therapeutics market: Market overview 2015
Exhibit 09: Global cystic fibrosis therapeutics market snapshot: Developed and emerging markets 2015
Exhibit 10: Global cystic fibrosis therapeutics market 2015-2020 ($ billions)
Exhibit 11: Opportunity analysis: Global cystic fibrosis therapeutics market
Exhibit 12: Impact of factors affecting the market 2015 and 2020
Exhibit 13: Five forces analysis
Exhibit 14: Global cystic fibrosis therapeutics by drug class 2015
Exhibit 15: Global cystic fibrosis therapeutics market by molecule type 2015
Exhibit 16: Global cystic fibrosis therapeutics market by geography 2015-2020
Exhibit 17: Percentage share of global cystic fibrosis therapeutics market by geography 2015 and 2020
Exhibit 18: Global cystic fibrosis therapeutics market by geography 2015-2020 ($ billions)
Exhibit 19: Global share of cystic fibrosis therapeutics market by geography 2015
Exhibit 20: Global cystic fibrosis therapeutics market by region: Market growth lifecycle analysis 2015
Exhibit 21: Global cystic fibrosis therapeutics market: Country analysis based on revenue and growth rate
Exhibit 22: Opportunity analysis: Cystic fibrosis therapeutics market in Americas
Exhibit 23: Cystic fibrosis therapeutics market in Americas 2015-2020 ($ billions)
Exhibit 24: Opportunity analysis: Cystic fibrosis therapeutics market in EMEA
Exhibit 25: Cystic fibrosis therapeutics market in EMEA 2015-2020 ($ billions)
Exhibit 26: Opportunity analysis: Cystic fibrosis therapeutics market in APAC
Exhibit 27: Cystic fibrosis therapeutics market in APAC 2015-2020 ($ millions)
Exhibit 28: Key leading countries for cystic fibrosis therapeutics market
Exhibit 29: Impact of drivers and challenges on global cystic fibrosis therapeutics market
Exhibit 30: Few drugs with breakthrough therapy designation for cystic fibrosis
Exhibit 31: Drugs with orphan drug designation for cystic fibrosis
Exhibit 32: Impact of drivers
Exhibit 33: Few cystic fibrosis therapeutics discontinued from development
Exhibit 34: Impact of drivers and challenges
Exhibit 35: Global cystic fibrosis therapeutics market: Impact assessment of key trends
Exhibit 36: Few cystic fibrosis therapeutics with patient assistance programs
Exhibit 37: Key vendors ranking 2015
Exhibit 38: Geographical presence of key vendors 2015
Exhibit 39: Competitive scenario of market vendors 2015-2020
Exhibit 40: Vertex Pharmaceuticals: Profile
Exhibit 41: Vertex Pharmaceuticals: Strength analysis
Exhibit 42: Vertex Pharmaceuticals: Growth strategy matrix
Exhibit 43: Vertex Pharmaceuticals: Opportunity assessment
Exhibit 44: Vertex Pharmaceuticals: Revenue of ORKAMBI and Kalydeco 2015 ($ millions)
Exhibit 45: F. Hoffmann-La Roche: Profile
Exhibit 46: F. Hoffmann-La Roche: Strength analysis
Exhibit 47: F. Hoffmann-La Roche: Growth strategy matrix
Exhibit 48: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 49: F. Hoffmann-La Roche: YoY growth and revenue generated from sales of Pulmozyme 2013-2015 ($ millions)
Exhibit 50: AbbVie: Profile
Exhibit 51: AbbVie: Strength analysis
Exhibit 52: AbbVie: Growth strategy matrix
Exhibit 53: AbbVie: Opportunity assessment
Exhibit 54: AbbVie: YoY growth and revenue of Creon 2013-2015 ($ millions)
Exhibit 55: Gilead Sciences: Profile
Exhibit 56: Gilead Sciences: Strength analysis
Exhibit 57: Gilead Sciences: Growth strategy matrix
Exhibit 58: Gilead Sciences: Opportunity assessment
Exhibit 59: Novartis: Profile
Exhibit 60: Novartis: Strength analysis
Exhibit 61: Novartis: Growth strategy matrix
Exhibit 62: Novartis: Opportunity assessment



【掲載企業】

Vertex Pharmaceuticals, F. Hoffmann-La Roche, AbbVie, Gilead Sciences, Novartis, Advanced Inhalation Therapies (AIT), Alaxia SAS, Alcresta Therapeutics, AlgiPharma, Allergan, Anthera, AstraZeneca, Bayer, Celtaxsys, Chiesi Farmaceutici, Corbus Pharmaceuticals, Cyclacel Pharmaceuticals, Digestive Care, Galapagos, Grifols, Insmed Incorporated, Kamada, Nivalis Therapeutics, Novoteris, Parion Sciences, Pharmaxis, ProQR Therapeutics, Protalix Biotherapeutics, Proteostasis Therapeutics, PTC Therapeutics, Pulmatrix, Savara, SolAeroMed, Vectura.

【レポートのキーワード】

嚢胞性線維症治療薬、医薬品、CF症

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[嚢胞性線維症(CF症)治療薬の世界市場2016-2020]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。
※当サイトでは2016年12月05日現在 219,162 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆